Literature DB >> 2833304

Can AZT treatment in AIDS patients aggravate pre-existing CMV retinitis?

E R Büchi, E H Bovey, A E Michel, P A Erard, J P Chave.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2833304      PMCID： PMC1041417          DOI： 10.1136/bjo.72.3.239

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  5 in total

1.  Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease.

Authors:  J S Pepose; G N Holland; M S Nestor; A J Cochran; R Y Foos
Journal:  Ophthalmology       Date:  1985-04       Impact factor: 12.079

2.  Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS.

Authors:  K Henry; H Cantrill; C Fletcher; B J Chinnock; H H Balfour
Journal:  Am J Ophthalmol       Date:  1987-01-15       Impact factor: 5.258

3.  Antiviral therapy for cytomegalovirus retinitis in AIDS with dihydroxy propoxymethyl guanine.

Authors:  L R Rosecan; C M Stahl-Bayliss; C M Kalman; O L Laskin
Journal:  Am J Ophthalmol       Date:  1986-04-15       Impact factor: 5.258

Review 4.  Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report.

Authors:  R Yarchoan; S Broder
Journal:  N Engl J Med       Date:  1987-02-26       Impact factor: 91.245

5.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205
  5 in total
  1 in total

Review 1.  Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  H D Langtry; D M Campoli-Richards
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.